Gilead Sciences, Assembly Biosciences Have Announced 12-Year Partnership For Antiviral Therapies, With An Initial Focus On Assembly Bio's Herpesviruses, Hepatitis B Virus, And Hepatitis D Virus; Assembly Bio To Receive $100M Upfront Payment
Gilead Sciences, Assembly Biosciences Have Announced 12-Year Partnership For Antiviral Therapies, With An Initial Focus On Assembly Bio's Herpesviruses, Hepatitis B Virus, And Hepatitis D Virus; Assembly Bio To Receive $100M Upfront Payment
吉利德科學和Assembly Biosciences宣佈了爲期12年的抗病毒療法合作伙伴關係，最初的重點是Assembly Bio的皰疹病毒、乙型肝炎病毒和丁型肝炎病毒；Assembly Bio將獲得1億美元的預付款
Gilead Sciences, Assembly Biosciences Have Announced 12-Year Partnership For Antiviral Therapies, With An Initial Focus On Assembly Bio's Herpesviruses, Hepatitis B Virus, And Hepatitis D Virus; Assembly Bio To Receive $100M Upfront Payment
吉利德科學公司、Assembly Biosciences公司宣佈了為期12年的抗病毒治療合作夥伴關係，最初的重點是Assembly Bio公司的皰疹病毒、乙肝病毒和丁型肝炎病毒；Assembly Bio公司將獲得1億美元的預付款